EMBC EMBECTA CORP

Embecta to host Analyst and Investor Day on May 22, 2025

Embecta to host Analyst and Investor Day on May 22, 2025

PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City.

Dev Kurdikar, President & Chief Executive Officer, and Jake Elguicze, Chief Financial Officer, will be joined by members of the embecta leadership team to present strategic and business overview, including value creation opportunities, the company’s financial profile and its long-term objectives.

To register for the webcast, please go to: .

Visit to view the agenda for the event and watch the live webcast. A replay of the webcast, along with Investor Day materials, will be available on the "Events & Presentations" section of the Company's Investor Relations website following the conclusion of the event.

In-person attendance is by invitation only.

About embecta 

embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit  or follow our social channels on , , and .

Contacts:

MediaInvestors
Christian GlazarPravesh Khandelwal
Sr. Director, Corporate CommunicationsVP, Head of Investor Relations
908-821-6922551-264-6547


EN
28/04/2025

Underlying

EMBCEMBECTA CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EMBECTA CORP

 PRESS RELEASE
Free
EMBC EMBECTA CORP

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at . About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medica...

7h / 49m 1 EN
 PRESS RELEASE
Free
EMBC EMBECTA CORP

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financi...

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2025. "Our fourth quarter results were largely in line with our expectations, with revenue lower year over year due to several items we had previously anticipated, including the impact of advanced distributor ordering in th...

November 25, 2025 1 EN
 PRESS RELEASE
Free
EMBC EMBECTA CORP

embecta Announces Quarterly Cash Dividend

embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025. About embectaembecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative soluti...

November 25, 2025 1 EN
 PRESS RELEASE
Free
EMBC EMBECTA CORP

embecta announces changes to Board of Directors

embecta announces changes to Board of Directors PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J. Albritton, a member of the Board of Directors (the “Board”) of embecta, has resigned from the Board due to personal reasons, effective immediately. In addition, LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board, has informed the company that he will not stand for re-election at embe...

November 17, 2025 1 EN
 PRESS RELEASE
Free
EMBC EMBECTA CORP

embecta Announces Major New Commitment to Direct Relief on World Diabe...

embecta Announces Major New Commitment to Direct Relief on World Diabetes Day Expanded Partnership Will Increase Access to Diabetes Care for Communities Across the U.S. and Globally PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced a significant expansion of its partnership with Direct Relief, the leading humanitarian aid organization and largest charitable insulin provider in the United States. In 2022, embecta was spun off from Becton,...

November 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch